{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:38:40Z","timestamp":1790437120880,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004117","name":"A.G. Leventis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.omtm.2020.05.017","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T21:49:25Z","timestamp":1590097765000},"page":"230-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Circulating Biomarkers in Muscular Dystrophies: Disease and Therapy Monitoring"],"prefix":"10.1016","volume":"18","author":[{"given":"Andrie","family":"Koutsoulidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas A.","family":"Phylactou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2020.05.017_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2014.4621","article-title":"Advances in muscular dystrophies","volume":"72","author":"Kang","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2020.05.017_bib2","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/neuonc\/nox242","article-title":"(2018). The FDA NIH biomarkers, endpoints, and other tools (BEST) resource in neuro-oncology","volume":"20","author":"Cagney","year":"2017","journal-title":"Neuro-oncol."},{"key":"10.1016\/j.omtm.2020.05.017_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.nmd.2018.05.007","article-title":"229th ENMC international workshop: limb girdle muscular dystrophies\u2014momenclature and reformed classification Naarden, the Netherlands, 17\u201319 March 2017","volume":"28","author":"Straub","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.05.017_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","article-title":"Duchenne and Becker muscular dystrophies","volume":"32","author":"Flanigan","year":"2014","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.omtm.2020.05.017_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.nmd.2013.05.006","article-title":"Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids","volume":"23","author":"Goemans","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.05.017_bib6","article-title":"Creatine kinase: a review of its use in the diagnosis of muscle disease","volume":"88","author":"Gasper","year":"2005","journal-title":"Med. Health R. I."},{"key":"10.1016\/j.omtm.2020.05.017_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201700071","article-title":"Mass spectrometry-based protein analysis to unravel the tissue pathophysiology in Duchenne muscular dystrophy","volume":"12","author":"Carr","year":"2018","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.omtm.2020.05.017_bib8","first-page":"1","article-title":"Biomarkers of Duchenne muscular dystrophy: current findings","volume":"8","author":"Szigyarto","year":"2018","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2020.05.017_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.molmed.2017.09.002","article-title":"Biomarker potential of extracellular miRNAs in Duchenne muscular dystrophy","volume":"23","author":"Coenen-Stass","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2020.05.017_bib10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1177\/0192623317734823","article-title":"Duchenne and Becker muscular dystrophies: a review of animal models, clinical end points, and biomarker quantification","volume":"45","author":"Wilson","year":"2017","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtm.2020.05.017_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-7046-9_4","article-title":"MicroRNAs: Biomarkers, Diagnostics, and Therapeutics","volume":"1617","author":"Huang","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omtm.2020.05.017_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-213X-11-34","article-title":"Expression of miR-1, miR-133a, miR-133b and miR-206 increases during development of human skeletal muscle","volume":"11","author":"Koutsoulidou","year":"2011","journal-title":"BMC Dev. Biol."},{"key":"10.1016\/j.omtm.2020.05.017_bib13","first-page":"3631","article-title":"MyoD transcription factor induces myogenesis by inhibiting Twist-1 through miR-206","volume":"128","author":"Koutalianos","year":"2015","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtm.2020.05.017_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ydbio.2015.12.013","article-title":"Muscle-specific microRNAs in skeletal muscle development","volume":"410","author":"Horak","year":"2016","journal-title":"Dev. Biol."},{"key":"10.1016\/j.omtm.2020.05.017_bib15","doi-asserted-by":"crossref","first-page":"e55281","DOI":"10.1371\/journal.pone.0055281","article-title":"Distinctive serum miRNA profile in mouse models of striated muscular pathologies","volume":"8","author":"Vignier","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib16","doi-asserted-by":"crossref","first-page":"e18388","DOI":"10.1371\/journal.pone.0018388","article-title":"Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy","volume":"6","author":"Mizuno","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib17","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1038\/mtna.2012.26","article-title":"Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy","volume":"1","author":"Roberts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2020.05.017_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/emmm.201100133","article-title":"miRNAs as serum biomarkers for Duchenne muscular dystrophy","volume":"3","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2020.05.017_bib19","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1093\/nar\/gkt724","article-title":"Extracellular microRNAs are dynamic non-vesicular biomarkers of muscle turnover","volume":"41","author":"Roberts","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2020.05.017_bib20","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/hmg\/ddw237","article-title":"Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation","volume":"25","author":"Coenen-Stass","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.05.017_bib21","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.ajpath.2014.07.021","article-title":"Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in golden retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients","volume":"184","author":"Jeanson-Leh","year":"2014","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtm.2020.05.017_bib22","doi-asserted-by":"crossref","first-page":"e80263","DOI":"10.1371\/journal.pone.0080263","article-title":"Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy","volume":"8","author":"Zaharieva","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtm.2020.05.017_bib24","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2020.05.017_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/mt.2010.261","article-title":"Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice","volume":"19","author":"Malerba","year":"2011","journal-title":"Mol. Ther"},{"key":"10.1016\/j.omtm.2020.05.017_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2018.08.005","article-title":"Comprehensive RNA-sequencing analysis in serum and muscle reveals novel small RNA signatures with biomarker potential for DMD","volume":"13","author":"Coenen-Stass","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2020.05.017_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nmd.2016.11.003","article-title":"Digital PCR quantification of miR-30c and miR-181a as serum biomarkers for Duchenne muscular dystrophy","volume":"27","author":"Llano-Diez","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.05.017_bib28","doi-asserted-by":"crossref","first-page":"e0145107","DOI":"10.1371\/journal.pone.0145107","article-title":"Transcriptome analysis of Ullrich congenital muscular dystrophy fibroblasts reveals a disease extracellular matrix signature and key molecular regulators","volume":"10","author":"Paco","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib29","doi-asserted-by":"crossref","first-page":"e0211597","DOI":"10.1371\/journal.pone.0211597","article-title":"Characterization of a novel microRNA, miR-188, elevated in serum of muscular dystrophy dog model","volume":"14","author":"Shibasaki","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib30","doi-asserted-by":"crossref","first-page":"ra81","DOI":"10.1126\/scisignal.2000610","article-title":"Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection","volume":"2","author":"Zernecke","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omtm.2020.05.017_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.tcb.2011.12.001","article-title":"Secreted microRNAs: a new form of intercellular communication","volume":"22","author":"Chen","year":"2012","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.omtm.2020.05.017_bib32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s12199-014-0405-7","article-title":"Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy","volume":"19","author":"Matsuzaka","year":"2014","journal-title":"Environ. Health Prev. Med."},{"key":"10.1016\/j.omtm.2020.05.017_bib33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7150\/thno.18133","article-title":"Progress in exosome isolation techniques","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.omtm.2020.05.017_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma proteomics","volume":"13","author":"Geyer","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.omtm.2020.05.017_bib35","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1073\/pnas.1507719112","article-title":"Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy","volume":"112","author":"Hathout","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2020.05.017_bib36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/jcsm.12304","article-title":"Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies","volume":"9","author":"Spitali","year":"2018","journal-title":"J.\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtm.2020.05.017_bib37","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1093\/hmg\/ddv214","article-title":"Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies","volume":"24","author":"Rouillon","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.05.017_bib38","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nmd.2011.05.011","article-title":"Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)","volume":"21","author":"Nadarajah","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.05.017_bib39","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.3390\/molecules200611154","article-title":"Non-invasive biomarkers for Duchenne muscular dystrophy and carrier detection","volume":"20","author":"Anaya-Segura","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.omtm.2020.05.017_bib40","doi-asserted-by":"crossref","first-page":"17888","DOI":"10.1038\/s41598-017-17982-y","article-title":"Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne","volume":"7","author":"Lourbakos","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.05.017_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/prca.201300072","article-title":"Fibronectin is a serum biomarker for Duchenne muscular dystrophy","volume":"8","author":"Cynthia Martin","year":"2014","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.omtm.2020.05.017_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3233\/JND-140066","article-title":"Muscle-derived proteins as serum biomarkers for monitoring disease progression in three forms of muscular dystrophy","volume":"2","author":"Burch","year":"2015","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2020.05.017_bib43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.15252\/emmm.201303724","article-title":"Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies","volume":"6","author":"Ayoglu","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2020.05.017_bib44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/prca.201500044","article-title":"Comparative mass spectrometric and immunoassay-based proteome analysis in serum of Duchenne muscular dystrophy patients","volume":"10","author":"Oonk","year":"2016","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.omtm.2020.05.017_bib45","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1093\/hmg\/ddu366","article-title":"Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients","volume":"23","author":"Hathout","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.05.017_bib46","doi-asserted-by":"crossref","first-page":"17014","DOI":"10.1038\/srep17014","article-title":"Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics","volume":"5","author":"Coenen-Stass","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.05.017_bib47","doi-asserted-by":"crossref","first-page":"e0153461","DOI":"10.1371\/journal.pone.0153461","article-title":"Discovery of metabolic biomarkers for Duchenne muscular dystrophy within a natural history study","volume":"11","author":"Boca","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib48","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/jcmm.13543","article-title":"Cross-sectional serum metabolomic study of multiple forms of muscular dystrophy","volume":"22","author":"Spitali","year":"2018","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.omtm.2020.05.017_bib49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcsm.12517","article-title":"Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy","volume":"11","author":"Signorelli","year":"2020","journal-title":"J.\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.omtm.2020.05.017_bib50","doi-asserted-by":"crossref","first-page":"31727","DOI":"10.1038\/srep31727","article-title":"Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children","volume":"6","author":"Hathout","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.05.017_bib51","doi-asserted-by":"crossref","first-page":"12167","DOI":"10.1038\/s41598-019-48548-9","article-title":"Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne muscular dystrophy","volume":"9","author":"Hathout","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.05.017_bib52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cyto.2017.12.006","article-title":"Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy","volume":"102","author":"de Carvalho","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.omtm.2020.05.017_bib53","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/hmg\/ddz309","article-title":"Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models","volume":"29","author":"Tsonaka","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.05.017_bib54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/jnnp.2008.158261","article-title":"The myotonic dystrophies: diagnosis and management","volume":"81","author":"Turner","year":"2010","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtm.2020.05.017_bib55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.nmd.2014.02.005","article-title":"Plasma microRNAs as biomarkers for myotonic dystrophy type 1","volume":"24","author":"Perfetti","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.05.017_bib56","doi-asserted-by":"crossref","first-page":"e0125341","DOI":"10.1371\/journal.pone.0125341","article-title":"Elevated muscle-specific miRNAs in serum of myotonic dystrophy patients relate to muscle disease progress","volume":"10","author":"Koutsoulidou","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2020.05.017_bib57","doi-asserted-by":"crossref","first-page":"38174","DOI":"10.1038\/srep38174","article-title":"Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1","volume":"6","author":"Perfetti","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2020.05.017_bib58","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1093\/hmg\/ddx212","article-title":"Identification of exosomal muscle-specific miRNAs in serum of myotonic dystrophy patients relating to muscle disease progress","volume":"26","author":"Koutsoulidou","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2020.05.017_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jnnp-2013-307052","article-title":"Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s)","volume":"86","author":"Yonekawa","year":"2015","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtm.2020.05.017_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/bs.ctm.2015.05.002","article-title":"Laminin-\u03b12 chain-deficient congenital muscular dystrophy: pathophysiology and development of treatment","volume":"76","author":"Durbeej","year":"2015","journal-title":"Curr. Top. Membr."},{"key":"10.1016\/j.omtm.2020.05.017_bib61","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11910-016-0667-0","article-title":"Facioscapulohumeral dystrophy","volume":"16","author":"Wang","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.omtm.2020.05.017_bib62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/practneurol-2017-001799","article-title":"Making sense of the clinical spectrum of limb girdle muscular dystrophies","volume":"18","author":"Khadilkar","year":"2018","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.omtm.2020.05.017_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnagi.2014.00155","article-title":"Laminin \u03b12 chain-deficiency is associated with microRNA deregulation in skeletal muscle and plasma","volume":"6","author":"Holmberg","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.omtm.2020.05.017_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3233\/JND-140034","article-title":"Multiplex screen of serum biomarkers in facioscapulohumeral muscular dystrophy","volume":"1","author":"Statland","year":"2014","journal-title":"J.\u00a0Neuromuscul. Dis."},{"key":"10.1016\/j.omtm.2020.05.017_bib65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.nmd.2016.04.012","article-title":"A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD)","volume":"26","author":"Petek","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2020.05.017_bib66","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1177\/1740774513497541","article-title":"Analytical and clinical evaluation of biomarkers assays: when are biomarkers ready for prime time?","volume":"10","author":"Pennello","year":"2013","journal-title":"Clin. Trials"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050120301042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:24:56Z","timestamp":1762421096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050120301042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":66,"alternative-id":["S2329050120301042"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2020.05.017","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Biomarkers in Muscular Dystrophies: Disease and Therapy Monitoring","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2020.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}